Typhim Vi Injection, Solution
NDC Package 49281-790-20

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Typhim Vi (salmonella typhi ty2 vi polysaccharide antigen) injection is this vaccine is used to help prevent typhoid fever. This formulation utilizes a injection, solution delivery system. Marketed by Sanofi Vaccines Us Inc., this product is identified by NDC 49281-790 and is authorized under FDA application BLA103936.

Identification & Billing

NDC Package Code
49281-790-20
Package Description
1 VIAL, MULTI-DOSE in 1 PACKAGE / 10 mL in 1 VIAL, MULTI-DOSE (49281-790-38)
Product Code
49281-790
11-Digit Billing Format
49281079020
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk
  • RxCUI: 1486496 - Typhim Vi 0.5 ML Prefilled Syringe
  • RxCUI: 1486496 - 0.5 ML typhoid Vi polysaccharide vaccine, S typhi Ty2 strain 0.05 MG/ML Prefilled Syringe [Typhim VI]
  • RxCUI: 1486496 - 0.5 ML Typhim VI 0.05 MG/ML Prefilled Syringe
  • RxCUI: 1486496 - Typhim VI 25 MCG per 0.5 ML Prefilled Syringe
  • RxCUI: 807222 - typhoid Vi polysaccharide vaccine (generic for Typhim Vi) Injectable Solution

Clinical Specifications

Proprietary Name
Typhim Vi
Non-Proprietary Name
Salmonella Typhi Ty2 Vi Polysaccharide Antigen
Substance Name
Salmonella Typhi Ty2 Vi Polysaccharide Antigen
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Intramuscular - Administration within a muscle.
Active Ingredient(s)
SALMONELLA TYPHI TY2 VI POLYSACCHARIDE ANTIGEN 25 ug/.5mL
Pharmacologic Class
Usage Information
This vaccine is used to help prevent typhoid fever. Vaccines work by increasing the body's natural defense (immunity) against the bacteria that cause the infection. This vaccine is recommended for people who are traveling to areas where the infection is common (e.g., Africa, Asia, Central/South America), those who are in close contact to someone with persistent typhoid infection, and those who work with the bacteria (Salmonella typhi) in a laboratory. This vaccine is used to prevent the disease and will not treat typhoid fever or a persistent typhoid infection.

Regulatory & Marketing

Labeler Name
Sanofi Vaccines Us Inc.
Product Type
Vaccine
FDA Application #
BLA103936
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
11-28-1994
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (49281-790). Click a package code to view its specific billing and regulatory data.

49281-790-51
1 SYRINGE in 1 PACKAGE / .5 mL in 1 SYRINGE (49281-790-88)

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 49281-790-20 identifies a specific commercial package of 1 vial, multi-dose in 1 package / 10 ml in 1 vial, multi-dose (49281-790-38) of Typhim Vi, a vaccine label labeled by Sanofi Vaccines Us Inc.. This injection, solution is formulated for intramuscular use and contains salmonella typhi ty2 vi polysaccharide antigen as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sanofi Vaccines Us Inc. on November 28, 1994. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

This vaccine is used to help prevent typhoid fever. Vaccines work by increasing the body's natural defense (immunity) against the bacteria that cause the infection. This vaccine is recommended for people who are traveling to areas where the infection is common (e.g., Africa, Asia, Central/South America), those who are in close contact to someone with persistent typhoid infection, and those who work with the bacteria (Salmonella typhi) in a laboratory. This vaccine is used to prevent the disease and will not treat typhoid fever or a persistent typhoid infection.

How is this Sanofi Vaccines Us Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 49281079020. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
49281-790-20
11-Digit CMS (5-4-2)
49281-0790-20

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.